Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Frontiers of Medicine
Published in: Frontiers of Medicine 5/2022

26-04-2022 | Research Article

Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach

Authors: Liang Dai, Jingjuan Xu, Baocheng Liu, Yanqi Dang, Ruirui Wang, Lijie Zhuang, Dong Li, Lulu Jiao, Jianying Wang, Lei Zhang, Linda L. D. Zhong, Wenjun Zhou, Guang Ji

Published in: Frontiers of Medicine | Issue 5/2022

Login to get access
Metadata
Title
Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach
Authors
Liang Dai
Jingjuan Xu
Baocheng Liu
Yanqi Dang
Ruirui Wang
Lijie Zhuang
Dong Li
Lulu Jiao
Jianying Wang
Lei Zhang
Linda L. D. Zhong
Wenjun Zhou
Guang Ji
Publication date
26-04-2022
Publisher
Higher Education Press
Published in
Frontiers of Medicine / Issue 5/2022
Print ISSN: 2095-0217
Electronic ISSN: 2095-0225
DOI
https://doi.org/10.1007/s11684-021-0880-3

Other articles of this Issue 5/2022

Frontiers of Medicine 5/2022 Go to the issue

Research Article

Outcomes of patients awaiting lung transplantation after the implementation of donation after brain death at a single Chinese center

Review

Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives

Consensus

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Research Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

Research Article

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

Research Article

Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma